3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Stomach Neoplasms
1
Oligometastatic Prostate Cancer
1
Cholangiocarcinoma
1
Bile Duct Neoplasms
1
Advanced Non-Small Cell Lung Cancer
1
Adenocarcinoma Of Esophagus
1
Interventions
Docetaxel
5
S 1 (combination)
2
Carboplatin
2
zimberelimab
1
surufatinib
1
quemliclustat
1
pemigatinib
1
nimotuzumab
1
lorlatinib
1
cemiplimab
1
Vinorelbine
1
Pemetrexed
1
Paclitaxel
1
Gene Expression Profiling
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Advanced Non-Small Cell Lung Cancer
×
quemliclustat
×
Clear all
NCT05676931
2025-10-02
EDGE-Lung
Gilead Sciences
Phase 2
Active not recruiting
400 enrolled